



WHAT IS CLAIMED IS:

1. A compound having one of the Formulae V and VI:



or a pharmaceutically acceptable salt or prodrug thereof, wherein:

Ar₃ is optionally substituted aryl or optionally substituted heteroaryl;

R₁ and R₂ are independently hydrogen, alkyl or cycloalkyl;

R₃-R₁₀ are independently hydrogen, halo, haloalkyl, aryl, fused aryl, carbocyclic, a heterocyclic group, a heteroaryl group, alkyl, alkenyl, alkynyl, arylalkyl, arylalkenyl, arylalkynyl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, carbocycloalkyl, heterocycloalkyl, hydroxyalkyl, nitro, amino, cyano, acylamino, hydroxy, thiol, sulfonyl, phosphonyl, acyloxy, azido, alkoxy, aryloxy, heteroaryloxy, arylalkoxy, heteroarylalkoxy,

haloalkoxy, carboxy, carbonylamido or alkylthiol, each of which is optionally substituted;

with the proviso that when said compound is of Formula V and Ar₃ is unsubstituted phenyl then each of R₃-R₇ is other than NH₂, NHCH₃, NO₂, Cl or CF₃.

2. The compound of claim 1, wherein R₁ and R₂ are hydrogen.
3. The compound of claim 1, wherein at least one of R₃-R₇ is other than hydrogen.
4. The compound of claim 1, wherein Ar₃ is optionally substituted aryl.
5. The compound of claim 4, wherein Ar₃ is optionally substituted phenyl.
6. The compound of claim 1, wherein Ar₃ is optionally substituted heteroaryl.
7. The compound of claim 1, wherein said compound is of Formula V.
8. The compound of claim 7, wherein said compound is selected from the group consisting of:
 - N'-(2-Phenoxy-pyridine-3-carbonyl)-4-nitrobenzhydrazide;
 - N'-(2-Phenoxy-pyridine-3-carbonyl)-2-amino-5-nitrobenzhydrazide;
 - N'-[2-(4-Methylphenoxy)pyridine-3-carbonyl]-2-hydroxy-benzhydrazide;

N'-(2-Phenoxypyridine-3-carbonyl)-3-trifluoromethylbenzhydrazide;
N'-[2-(4-Methylphenoxy)pyridine-3-carbonyl]-3-(trifluoromethyl)-
benzhydrazide;
N'-(2-Phenoxypyridine-3-carbonyl)-3-hydroxybenzhydrazide;
N'-(2-Phenoxypyridine-3-carbonyl)-3-aminobenzhydrazide;
N'-(2-Phenoxypyridine-3-carbonyl)-4-(trifluoromethyl)benzhydrazide;
N'-(2-Phenoxypyridine-3-carbonyl)-4-hydroxybenzhydrazide;
N'-(2-Phenoxypyridine-3-carbonyl)-2-hydroxybenzhydrazide;
N'-(2-Phenoxypyridine-3-carbonyl)-2-(trifluoromethyl)benzhydrazide;
N'-(2-Phenoxypyridine-3-carbonyl)-3-fluorobenzhydrazide;
N'-(2-Phenoxypyridine-3-carbonyl)-3-nitrobenzhydrazide; and
N'-(2-Phenoxypyridine-3-carbonyl)-2-fluorobenzhydrazide;
and pharmaceutically acceptable salts and prodrugs thereof.

9. The compound of claim 1, wherein said compound is of Formula VI.

10. The compound of claim 9, said compound is selected from the group consisting of:

2-Phenoxypyridine-3-carboxylic acid (3-trifluoromethylbenzylidene)-hydrazide;

2-Phenoxypyridine-3-carboxylic acid (2-trifluoromethylbenzylidene)-hydrazide;

2-Phenoxypyridine-3-carboxylic acid (4-trifluoromethylbenzylidene)-hydrazide;

2-Phenoxypyridine-3-carboxylic acid (4-hydroxybenzylidene)-hydrazide;

2-(Pyridin-3-yloxy)-pyridine-3-carboxylic acid (3-trifluoromethylbenzylidene)-hydrazide;

2-Phenoxypyridine-3-carboxylic acid (3,5-bis(trifluoromethyl)benzylidene)-hydrazide;

2-Phenoxypyridine-3-carboxylic acid (3-methyl-benzylidene)-hydrazide;

2-Phenoxypyridine-3-carboxylic acid (2-hydroxylbenzylidene)-hydrazide;

2-Phenoxypyridine-3-carboxylic acid benzylidene-hydrazide;

2-Phenoxypyridine-3-carboxylic acid (2,5-bis(trifluoromethyl)-benzylidene)-hydrazide;

2-Phenoxypyridine-3-carboxylic acid (3-trifluoromethoxy-benzylidene)-hydrazide;

2-Phenoxypyridine-3-carboxylic acid (3-chlorobenzylidene)-hydrazide; and

2-Phenoxypyridine-3-carboxylic acid (3,4-difluoro-5-trifluoromethyl-benzylidene)-hydrazide;

and pharmaceutically acceptable salts and prodrugs thereof.

11. A compound selected from the group consisting of:

N'-[5-(1-Hexynyl)pyridine-3-carbonyl]-3-(trifluoromethyl)-benzhydrazide;

N'-(Pyridine-3-carbonyl)-4-bromobenzhydrazide;

N'-(2-Phenoxypyridine-3-carbonyl)-(N-oxide-pyridine-3-carbonyl)-hydrazide;

N'-(2-Phenoxypyridine-3-carbonyl)-(pyridine-3-carbonyl)hydrazide;

N'-[2-(Methylthio)pyridine-3-carbonyl]-3-(trifluoromethyl)-benzhydrazide;

2-Phenoxypyridine-3-carboxylic acid (3-pyridylmethylidene)-hydrazide; and

2-Phenoxypyridine-3-carboxylic acid (4-pyridylmethylidene)-hydrazide;

2-Chloropyridine-3-carboxylic acid (3-trifluoromethyl-benzylidene)-hydrazide;

2-Anilinopyridine-3-carboxylic acid (3-trifluoromethyl-benzylidene)-

hydrazide;

Biphenyl-2-carboxylic acid (3-trifluoromethyl-benzylidene)-hydrazide;

2-(3-Trifluoromethyl-anilino)-pyridine-3-carboxylic acid (3-trifluoromethyl-benzylidene)-hydrazide;

3,4,5-Trimethoxy-benzoic acid (3-trifluoromethyl-benzylidene)-hydrazide;

3,4-Dihydroxy-benzoic acid (3-trifluoromethyl-benzylidene)-hydrazide;

4-(Pyridin-4-yl)-2-(pyridin-2-yl)pyrimidine-5-carboxylic acid (3-trifluoromethyl-benzylidene)-hydrazide;

5-Amino-2-phenoxy-benzoic acid (3-trifluoromethyl-benzylidene)-hydrazide;

2-(Morpholin-4-ylmethyl)-benzoic acid (3-trifluoromethyl-benzylidene)-hydrazide;

5-Nitro-2-phenoxy-benzoic acid (3-trifluoromethyl-benzylidene)-hydrazide;

2-[1-(6-Chloro-pyridin-2-yl)-1H-[1,2,4]triazol-3ylmethoxy]-benzoic acid (3-trifluoromethyl-benzylidene)-hydrazide;

2-Phenoxybenzoic acid (3-trifluoromethylbenzylidene)-hydrazide; and

2-Phenoxybenzoic acid (2-hydroxybenzylidene)-hydrazide;

and pharmaceutically acceptable salts and prodrugs thereof.



12. A pharmaceutical composition, comprising the compound of claim 1, 8, 10 or 11, and a pharmaceutically acceptable carrier.

13. The pharmaceutical composition of claim 12, further comprising at least one known cancer chemotherapeutic agent, or a pharmaceutically acceptable salt of said agent.

14. The pharmaceutical composition of claim 13, wherein said known cancer chemotherapeutic agent is selected from the group consisting of

busulfan, cis-platin, mitomycin C, carboplatin, colchicine, vinblastine, paclitaxel, docetaxel, camptothecin, topotecan, doxorubicin, etoposide, 5-azacytidine, 5-fluorouracil, methotrexate, 5-fluoro-2'-deoxy-uridine, ara-C, hydroxyurea, thioguanine, melphalan, chlorambucil, cyclophosphamide, ifosfamide, vincristine, mitoguazone, epirubicin, aclarubicin, bleomycin, mitoxantrone, elliptinium, fludarabine, octreotide, retinoic acid, tamoxifen, Herceptin®, Rituxan® and alanosine.

15. A method of treating a disorder responsive to the induction of apoptosis in an animal suffering therefrom, comprising administering to an animal in need of such treatment an effective amount of a compound having one of the Formulae I and II:



or a pharmaceutically acceptable salt or prodrug thereof, wherein:

Ar₁ is optionally substituted pyridyl, optionally substituted pyrimidinyl or optionally substituted phenyl;

Ar₂ is optionally substituted aryl or optionally substituted heteroaryl; and



R₁ and R₂ are independently hydrogen, alkyl or cycloalkyl;

with the proviso that said compound is other than 4-hydroxybenzoic acid (2-hydroxybenzylidene)-hydrazide.

16. The method of claim 15, wherein said animal is a mammal.
17. The method of claim 15, wherein R_1 and R_2 are hydrogen.
18. The method of claim 15, wherein said compound is of Formula I.
19. The method of claim 15, wherein said compound is of Formula II.
20. The method of claim 15, wherein Ar_1 is optionally substituted pyridyl.
21. The method of claim 20, wherein Ar_1 is optionally substituted phenyl.
22. The method of claim 15, wherein Ar_2 is optionally substituted aryl.
23. The method of claim 22, wherein Ar_2 is optionally substituted phenyl.
24. The method of claim 15, wherein Ar_2 is optionally substituted heteroaryl.
25. The method of claim 15, with the further provisos that:
 - (a) when said compound is of Formula I and Ar_1 is ((unsubstituted)phenoxy)pyridyl then Ar_2 is other than (i) phenyl which is substituted by NH_2 , $NHCH_3$, NO_2 , Cl or CF_3 and (ii) (unsubstituted)phenoxypyridyl; and
 - (b) when said compound is of Formula I and Ar_1 is unsubstituted pyridyl, 6-chloropyrid-3-yl or 2-(2-trifluoroethoxy)pyrid-3-yl then Ar_2 is other than dichlorophenyl.

26. The method of claim 15, with the further proviso that when said compound is of Formula II and Ar₁ is mono-substituted-4-phenyl then Ar₂ is other than mono-substituted-2-phenyl.

27. The method of claim 15, wherein said compound has one of the Formulae III and IV:



or a pharmaceutically acceptable salt or prodrug thereof, wherein:

R₁ and R₂ are independently hydrogen, alkyl or cycloalkyl;

R₃-R₁₁ are independently hydrogen, halo, haloalkyl, aryl, fused aryl, carbocyclic, a heterocyclic group, a heteroaryl group, alkyl, alkenyl, alkynyl, arylalkyl, arylalkenyl, arylalkynyl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, carbocycloalkyl, heterocycloalkyl, hydroxyalkyl, nitro,

amino, cyano, acylamino, hydroxy, thiol, sulfonyl, phosphonyl, acyloxy, azido, alkoxy, aryloxy, heteroaryloxy, arylalkoxy, heteroarylalkoxy, haloalkoxy, carboxy, carbonylamido or alkylthiol, each of which is optionally substituted.

28. The method of claim 27, wherein R_1 and R_2 are hydrogen.

29. The method of claim 27, wherein R_3 - R_{10} independently are hydrogen, halogen, methyl, trifluoromethyl, hydroxy, methoxy, NH_2 , $NHCH_3$ or $N(CH_3)_2$.

30. The method of claim 27, wherein said compound is of Formula III.

31. The method of claim 30, wherein said compound is selected from the group consisting of:

N' -[5-(1-Hexynyl)pyridine-3-carbonyl]-3-(trifluoromethyl)-benzhydrazide;

N' -(Pyridine-3-carbonyl)-4-bromobenzhydrazide; and

N' -[2-Methylthio]pyridine-3-carbonyl]-3-(trifluoromethyl)-benzhydrazide;

and pharmaceutically acceptable salts and prodrugs thereof.

32. The method of claim 27, wherein said compound is of Formula IV.

33. The method of claim 32, wherein said compound is selected from the group consisting of:

2-Chloropyridine-3-carboxylic acid (3-trifluoromethyl-benzylidene)-hydrazide;


2-Anilinopyridine-3-carboxylic acid (3-trifluoromethyl-benzylidene)-hydrazide; and

2-(3-Trifluoromethyl-anilino)-pyridine-3-carboxylic acid (3-trifluoromethyl-benzylidene)-hydrazide;

and pharmaceutically acceptable salts and prodrugs thereof.


34. The method of claim 27, with the provisos that:

(a) when each of R_8 - R_{10} is hydrogen and R_{11} is unsubstituted phenoxy then




is other than phenyl which is substituted by NH_2 , $NHCH_3$, NO_2 , Cl or CF_3 ;

(b) when each of R_8 - R_{10} is hydrogen and R_{11} is hydrogen or 2-trifluoroethoxy then



is other than dichlorophenyl; and



(c) when each of R_8 , R_9 and R_{11} is hydrogen and R_{10} is chloro then



is other than dichlorophenyl.

35. The method of claim 27, wherein said compound has one of the

Formulae V and VI:



or a pharmaceutically acceptable salt or prodrug thereof, wherein:

Ar₃ is optionally substituted aryl or optionally substituted heteroaryl;

R₁ and R₂ are independently hydrogen, alkyl or cycloalkyl;

R₃-R₁₀ are independently hydrogen, halo, haloalkyl, aryl, fused aryl, carbocyclic, a heterocyclic group, a heteroaryl group, alkyl, alkenyl, alkynyl, arylalkyl, arylalkenyl, arylalkynyl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, carbocycloalkyl, heterocycloalkyl, hydroxyalkyl, nitro, amino, cyano, acylamino, hydroxy, thiol, sulfonyl, phosphonyl, acyloxy, azido, alkoxy, aryloxy, heteroaryloxy, arylalkoxy, heteroarylalkoxy, haloalkoxy, carboxy, carbonylamido or alkylthiol, each of which is optionally substituted.

36. The method of claim 35, wherein R_1 and R_2 are hydrogen.
37. The method of claim 35, wherein R_3 - R_{10} independently are hydrogen, halogen, methyl, trifluoromethyl, hydroxy, methoxy, NH_2 , $NHCH_3$ or $N(CH_3)_2$.
38. The method of claim 35, wherein Ar_3 is optionally substituted aryl.
39. The method of claim 38, wherein Ar_3 is optionally substituted phenyl.
40. The method of claim 35, wherein Ar_3 is optionally substituted heteroaryl.
41. The method of claim 35, wherein said compound is of Formula V.
42. The method of claim 41, wherein said compound is selected from the group consisting of:
- N' -(2-Phenoxypyridine-3-carbonyl)-4-nitrobenzhydrazide;
 - N' -(2-Phenoxypyridine-3-carbonyl)-2-amino-5-nitrobenzhydrazide;
 - N' -[2-(4-Methylphenoxy)pyridine-3-carbonyl]-2-hydroxybenzhydrazide;
 - N' -(2-Phenoxypyridine-3-carbonyl)-3-trifluoromethylbenzhydrazide;
 - N' -[2-(4-Methylphenoxy)pyridine-3-carbonyl]-3-(trifluoromethyl)benzhydrazide;
 - N' -(2-Phenoxypyridine-3-carbonyl)-3-hydroxybenzhydrazide;
 - N' -(2-Phenoxypyridine-3-carbonyl)-3-aminobenzhydrazide;
 - N' -(2-Phenoxypyridine-3-carbonyl)-4-(trifluoromethyl)benzhydrazide;
 - N' -(2-Phenoxypyridine-3-carbonyl)-4-hydroxybenzhydrazide;
 - N' -(2-Phenoxypyridine-3-carbonyl)-2-hydroxybenzhydrazide;

N'-(2-Phenoxypyridine-3-carbonyl)-2-(trifluoromethyl)benzhydrazide;
N'-(2-Phenoxypyridine-3-carbonyl)-3-fluorobenzhydrazide;
N'-(2-Phenoxypyridine-3-carbonyl)-3-nitrobenzhydrazide; and
N'-(2-Phenoxypyridine-3-carbonyl)-2-fluorobenzhydrazide;
and pharmaceutically acceptable salts and prodrugs thereof.

43. The method of claim 35, wherein said compound is of Formula VI.

44. The method of claim 43, wherein said compound is selected from the group consisting of:

2-Phenoxypyridine-3-carboxylic acid (3-trifluoromethylbenzylidene)-hydrazide;

2-Phenoxypyridine-3-carboxylic acid (2-trifluoromethylbenzylidene)-hydrazide;

2-Phenoxypyridine-3-carboxylic acid (4-trifluoromethylbenzylidene)-hydrazide;

2-Phenoxypyridine-3-carboxylic acid (4-hydroxybenzylidene)-hydrazide;

2-(Pyridin-3-yloxy)-pyridine-3-carboxylic acid (3-trifluoromethylbenzylidene)-hydrazide;

2-Phenoxypyridine-3-carboxylic acid (3,5-bis(trifluoromethyl)benzylidene)-hydrazide;

2-Phenoxypyridine-3-carboxylic acid (3-methylbenzylidene)-hydrazide;

2-Phenoxypyridine-3-carboxylic acid (2-hydroxybenzylidene)-hydrazide;

2-Phenoxypyridine-3-carboxylic acid benzylidene-hydrazide;

2-Phenoxypyridine-3-carboxylic acid (2,5-bis(trifluoromethyl)benzylidene)-hydrazide;


2-Phenoxypyridine-3-carboxylic acid (3-trifluoromethoxybenzylidene)-hydrazide;

2-Phenoxypyridine-3-carboxylic acid (3-chlorobenzylidene)-hydrazide; and

2-Phenoxypyridine-3-carboxylic acid (3,4-difluoro-5-trifluoromethylbenzylidene)-hydrazide;

and pharmaceutically acceptable salts and prodrugs thereof.

45. The method of claim 35, with the proviso that when each of R₈-R₁₀ is hydrogen and Ar₃ is unsubstituted phenyl then



is other than phenyl which is substituted NH₂, NHCH₃, NO₂, Cl or CF₃.

46. The method of claim 15, wherein said compound is selected from the group consisting of:

N'-(2-Phenoxypyridine-3-carbonyl)-(N-oxide-pyridine-3-carbonyl)-hydrazide;

N'-(2-Phenoxypyridine-3-carbonyl)-(pyridine-3-carbonyl)hydrazide;

2-Phenoxypyridine-3-carboxylic acid (3-pyridylmethylidene)-hydrazide; and

2-Phenoxypyridine-3-carboxylic acid (4-pyridylmethylidene)-hydrazide;

Biphenyl-2-carboxylic acid (3-trifluoromethyl-benzylidene)-hydrazide;

3,4,5-Trimethoxy-benzoic acid (3-trifluoromethyl-benzylidene)-hydrazide;

3,4-Dihydroxy-benzoic acid (3-trifluoromethyl-benzylidene)-hydrazide;

4-(Pyridin-4-yl)-2-(pyridin-2-yl)pyrimidine-5-carboxylic acid

(3-trifluoromethyl-benzylidene)-hydrazide;

5-Amino-2-phenoxy-benzoic acid (3-trifluoromethyl-benzylidene)-hydrazide;

2-(Morpholin-4-ylmethyl)-benzoic acid (3-trifluoromethyl-benzylidene)-hydrazide;

5-Nitro-2-phenoxy-benzoic acid (3-trifluoromethyl-benzylidene)-hydrazide;



2-[1-(6-Chloro-pyridin-2-yl)-1H-[1,2,4]triazol-3ylmethoxy]-benzoic acid (3-trifluoromethyl-benzylidene)-hydrazide;

2-Phenoxybenzoic acid (3-trifluoromethylbenzylidene)-hydrazide; and

2-Phenoxybenzoic acid (2-hydroxybenzylidene)-hydrazide;

and pharmaceutically acceptable salts and prodrugs thereof.

47. A method for treating or preventing cancer comprising administering to an animal in need of such treatment an effective amount of a compound having one of the Formulae I and II:



or a pharmaceutically acceptable salt or prodrug thereof, wherein:

Ar₁ is optionally substituted pyridyl, optionally substituted pyrimidinyl or optionally substituted phenyl;

Ar₂ is optionally substituted aryl or optionally substituted heteroaryl; and

R_1 and R_2 are independently hydrogen, alkyl or cycloalkyl;
with the proviso that said compound is other than 4-hydroxybenzoic acid
(2-hydroxybenzylidene)-hydrazide.

48. The method of claim 47, wherein said animal is a mammal.
49. The method of claim 47, wherein R_1 and R_2 are hydrogen.
50. The method of claim 47, wherein said compound is of Formula I.
51. The method of claim 47, wherein said compound is of Formula II.
52. The method of claim 47, wherein Ar_2 is optionally substituted aryl.
53. The method of claim 52, wherein Ar_2 is optionally substituted phenyl.
54. The method of claim 47, wherein Ar_2 is optionally substituted heteroaryl.
55. The method of claim 47, wherein said cancer is selected from the group consisting of Hodgkin's disease, non-Hodgkin's lymphoma, acute lymphocytic leukemia, chronic lymphocytic leukemia, multiple myeloma, neuroblastoma, breast carcinoma, ovarian carcinoma, lung carcinoma, Wilms' tumor, cervical carcinoma, testicular carcinoma, soft-tissue sarcoma, primary macroglobulinemia, bladder carcinoma, chronic granulocytic leukemia, primary brain carcinoma, retinoblastoma, glioma, malignant melanoma, small-cell lung carcinoma, stomach carcinoma, colon carcinoma, malignant pancreatic insulinoma, malignant carcinoid carcinoma, malignant melanoma, choriocarcinoma, mycosis fungoides, head or neck carcinoma, osteogenic

sarcoma, pancreatic carcinoma, acute granulocytic leukemia, hairy cell leukemia, neuroblastoma, rhabdomyosarcoma, Kaposi's sarcoma, genitourinary carcinoma, thyroid carcinoma, esophageal carcinoma, malignant hypercalcemia, cervical hyperplasia, renal cell carcinoma, endometrial carcinoma, polycythemia vera, essential thrombocytosis, adrenal cortex carcinoma, skin cancer and prostatic carcinoma.

56. The method of claim 47, wherein said cancer is drug resistant and hormone dependent or independent breast carcinoma.



57. The method of claim 47, with the further provisos that:

(a) when Ar₁ is ((unsubstituted)phenoxy)pyridyl then Ar₂ is other than (i) phenyl which is substituted by NH₂, NHCH₃, NO₂, Cl or CF₃ and (ii) (unsubstituted)phenoxy pyridyl; and

(b) when Ar₁ is unsubstituted pyridyl, 6-chloropyrid-3-yl or 2-(2-trifluoroethoxy)pyrid-3-yl then Ar₂ is other than dichlorophenyl.

58. The method of claim 47, with the further proviso that when said compound is of Formula II and Ar₁ is mono-substituted-4-phenyl then Ar₂ is other than mono-substituted-2-phenyl.

59. A method for treating or preventing drug resistant cancer comprising administering to an animal in need of such treatment an effective amount of a compound having one of the Formulae I and II:



or a pharmaceutically acceptable salt or prodrug thereof, wherein:

Ar₁ is optionally substituted pyridyl, optionally substituted pyrimidinyl or optionally substituted phenyl;

Ar₂ is optionally substituted aryl or optionally substituted heteroaryl; and

R₁ and R₂ are independently hydrogen, alkyl or cycloalkyl.

60. The method of claim 59, wherein said animal is a mammal.
61. The method of claim 59, wherein R₁ and R₂ are hydrogen.
62. The method of claim 59, wherein said compound is of Formula I.
63. The method of claim 59, wherein said compound is of Formula II.
64. The method of claim 59, wherein Ar₂ is optionally substituted aryl.
65. The method of claim 64, wherein Ar₂ is optionally substituted phenyl.
66. The method of claim 59, wherein Ar₂ is optionally substituted heteroaryl.

67. The method of claim 47 or 59, additionally comprising administering at least one known cancer chemotherapeutic agent, or a pharmaceutically acceptable salt of said agent.

68. The method of claim 67, wherein said known cancer therapeutic agent is selected from the group consisting of busulfan, cis-platin, mitomycin C, carboplatin, colchicine, vinblastine, paclitaxel, docetaxel, camptothecin, topotecan, doxorubicin, etoposide, 5-azacytidine, 5-fluorouracil, methotrexate, 5-fluoro-2'-deoxy-uridine, ara-C, hydroxyurea, thioguanine, melphalan, chlorambucil, cyclophosphamide, ifosfamide, vincristine, mitoguazone, epirubicin, aclarubicin, bleomycin, mitoxantrone, elliptinium, fludarabine, octreotide, retinoic acid, tamoxifen, Herceptin® or Rituxan® and alanosine.

69. The method of claim 47 or 59, additionally comprising treating said animal with radiation-therapy.

70. The method of claim 47 or 59, wherein said compound is administered after surgical treatment of said animal for said cancer.

71. The method of claim 59, with the provisos that:

(a) when Ar₁ is ((unsubstituted)phenoxy)pyridyl then Ar₂ is other than (i) phenyl which is substituted by NH₂, NHCH₃, NO₂, Cl or CF₃ and (ii) (unsubstituted)phenoxy pyridyl; and

(b) when Ar₁ is unsubstituted pyridyl, 6-chloropyrid-3-yl or 2-(2-trifluoroethoxy)pyrid-3-yl then Ar₂ is other than dichlorophenyl.

72. The method of claim 59, with the proviso that said compound is other than 4-hydroxybenzoic acid (2-hydroxybenzylidene)-hydrazide.

73. The method of claim 59, with the proviso that when said compound is of Formula II and Ar₁ is mono-substituted-4-phenyl then Ar₂ is other than mono-substituted-2-phenyl.

74. The method of claim 15, wherein said disorder is an autoimmune disease.

75. The method of claim 15, wherein said disorder is an infectious viral disease.

76. The method of claim 15, wherein said disorder is rheumatoid arthritis.

77. The method of claim 15, wherein said disorder is inflammatory bowel disease.

78. The method of claim 15, wherein said disorder is a skin disease.

79. The method of claim 77, wherein said disorder is psoriasis.